Promoter holding
64.27%
BS
Brichem Sciences Private Limited - Due diligence report
A 360° intelligence report on Brichem Sciences: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Brichem Sciences — 360° Intelligence Report
Generated from MCA filings & public records71/100
Trust Score
Moderate
Brichem Sciences is assessed as Moderate with a Trust Score of 71/100. Brichem Sciences is an active private limited indian non-government company incorporated in 2016, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Brichem Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
71/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
63/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 38%).
- Profitable - internal accruals available.
Charges position: 1 open (12.30 cr) · 2 satisfied (19.20 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 2 | 48.0 cr |
| The Kalupur Commercial Co-Operative Bank Limited | 1 | 48.0 cr |
Compliance Score: 63/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 1 court forum(s).
- 2 auditor resignation(s) filed - latest: S M Vaghela and Co on 2021-04-02.
- Delayed payments to MSME suppliers disclosed (1 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAJESHKUMAR BECHARBHAI GAMI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PARAGKUMAR GUNVANTLAL BHAVSAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AASHAY JAYANTILAL PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MITTALKUMAR JAGDISHBHAI PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 9 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 9 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
1 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 41.36 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence69/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment52/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 12.30 cr already registered.
- Compliance gaps should be priced into terms.
Investor view73/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
26 Feb 2024
Charge satisfied
Others
22 Feb 2024
Charge created
Others - 12.30 cr
31 Mar 2023
Share transfer (FY 2023)
28550.00000000 shares to Nirav Patel
31 Mar 2021
Share transfer (FY 2021)
28550.00000000 shares to Hemal Naranbhai Patel
Share transfer (FY 2021)
2700.00000000 shares to Naimesh Kumar Haribhai Patel
23 Dec 2019
Securities allotted
125000 Equity Shares - 12.50 Lakh raised
28 Sep 2019
Director ceased
AASHAY JAYANTILAL PATEL
Director ceased
MITTALKUMAR JAGDISHBHAI PATEL
10 Sep 2019
Charge created
Others - 18.40 cr
31 Jul 2019
Director appointed
AASHAY JAYANTILAL PATEL (Director)
Director appointed
MITTALKUMAR JAGDISHBHAI PATEL (Director)
12 Jul 2019
Charge satisfied
The Kalupur Commercial Co-Operative Bank Limited
24 Jun 2019
Director ceased
TUSHARKUMAR RAMESHBHAI PATEL
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Synergy Poly Additives Private Limited | U25209HP2001PTC024553 | Himachal Pradesh, Himachal Pradesh, India |
| Millenium Cement Company Private Limited | U26922WB1999PTC088899 | Jalpaiguri, West Bengal, India |
| Shankus Pharma Private Limited | U24299GJ2021PTC127481 | Mehsana, Gujarat, India |
| Lark Laboratories | U24230DL1979PLC009548 | New Delhi, Delhi, India |
| Bueno Salud Care | U24304GJ2016PTC094652 | Ahmedabad, Gujarat, India |
| Saimirra | U24232TN2000PTC044315 | Chennai, Tamil Nadu, India |
| Mepromax Life Sciences Private Limited | U24231GJ2005PTC045918 | Wadhwan, Gujarat, India |
| Brooks Laboratories | L24232HP2002PLC000267 | Nalagarh, Himachal Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Brichem Sciences before audits and certifications: compliance score 63/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Brichem Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Brichem Sciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 71/100, distress signals and MSME payment-delay disclosures - know whether Brichem Sciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Brichem Sciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Brichem Sciences an active company?
Brichem Sciences has MCA status “Active” with a compliance score of 63/100 (Moderate).
Is Brichem Sciences financially healthy?
Brichem Sciences has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.
Should I do business with Brichem Sciences?
Its overall Trust Score is 71/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Brichem Sciences?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.
Does Brichem Sciences have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Brichem Sciences up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 63/100 (Moderate).
Is it risky to lend to Brichem Sciences?
Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
